Drugs / AAV8-hCARp.hCNGB3
AAV8-hCARp.hCNGB3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03001310 | Jan 2017 → Oct 2019 | achromatopsia | MeiraGTx UK II Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV8-hCARp.hCNGB3 | “First-in-Human Gene Therapy Trial of AAV8-hCARp.hCNGB3 in Adults and Children With CNGB3-associated Achromatopsia.” PMID 37172884 ↗ May 2023 |
| Modality | Gene therapy (AAV / viral vector) | “AAV8-hCARp.hCNGB3 gene therapy” PMID 37172884 ↗ May 2023 |
| Route | Other | “Subretinal administration of a single low dose of AAV - CNGB3” NCT03001310 ↗ |